Clinical trials: Normal Drug Tolerance
Acne Vulgaris
A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris
The study will look to evaluate the tolerance of a light therapy-based acne mask device in participants who report having sensitive skin.
- Trial name
- NCT03128723
- Testing
- Acne Mask
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Acne Vulgaris
A Study to Evaluate the Efficacy and Tolerance of 2 Acne Treatment Regimens on Subjects With Mild to Moderate Acne
This study will compare two different acne treatment regimens for the treatment of acne. Half of participants will receive a cleanser and a light therapy mask, while half of the participants will receive a cleanser, a light…
- Trial name
- NCT03124381
- Testing
- Cleanser, Acne Mask, Cleanser, Gel-Cream, Acne Mask
- Where
- 2 sites in United States
- Volunteers
- 126 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Fine Lines, Wrinkles
A Clinical Study Evaluating the Efficacy and Tolerability of a Topical Facial Treatment For Facial Rejuvenation
This single-center clinical trial was conducted to evaluate the efficacy and tolerability of a topical facial treatment when applied by a license esthetician in clinic in a series of 3 sessions with 1 month intervals, in…
- Conditions
- Fine Lines, Wrinkles, Laxity; Skin
- Trial name
- NCT06629792
- Testing
- Gentle Cleanser, Facial Moisturizer, sunscreen SPF 30
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Revision Skincare
Rosacea, Redness
Evaluation of the Efficacy and Tolerance of Two Cosmetic Products in Subjects With Rosacea
Multicentric and double-blind randomised comparative clinical study in Argentina and Brazil. Under dermatological and ophthalmological control 4 visits: inclusion [Day(D)0], D28, D56, D84 Ethical committee required.
- Conditions
- Rosacea, Redness, Telangiectasia, Flushing
- Trial name
- NCT06582043
- Testing
- SCARCr tester 1
- Where
- 2 sites in Argentina, Brazil
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- NAOS Argentina S.A.
Rheumatoid Arthritis
A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects
This study was a randomized, double-blind, placebo-controlled phase I clinical trial of TQH3821 in adult healthy subjects, which plans to recruit 72 healthy subjects.
- Trial name
- NCT05380934
- Testing
- TQH3821 tablets, Methotrexate tablets
- Where
- China
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
The purpose of this study is to assess rheumatologic tolerability of letrozole in postmenopausal patients with hormone receptor positive breast cancer having discontinued anastrozole adjuvant treatment due to musculoskeletal…
- Trial name
- NCT00329940
- Testing
- Letrozole
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus
A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)
The purpose of the study is to assess the Safety, Tolerability, PK/PD and preliminary Efficacy of ICP-022 in Subjects with Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT04305197
- Testing
- ICP-022
- Where
- 11 sites in China
- Volunteers
- 60 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Androgenic Alopecia
Assessment of the Effects and Tolerance of the RV4986A Lotion in Men With AGA After Hair Transplant
Alopecia involves a diminution of visible hair that can have significant psychosocial effects and impairment of quality of life.
- Trial name
- NCT06576492
- Testing
- RV4986A lotion
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Normal, Healthy Volunteers
A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020
To investigate whether there is a food-effect with oral administration with EB-1020 as well as to obtain information on the safety, and tolerability of EB-1020 in a range of doses.
- Trial name
- NCT01744808
- Testing
- EB-1020 IR, EB-1020 SR1, EB-1020 SR2
- Where
- Australia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Normal Drug Tolerance
Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women
This is a phase 1, open-label, randomized pharmacokinetic and safety study in healthy adult subjects, who will undergo bronchoscopy and bronchoalveolar lavage (BAL) after receiving seven (7) doses of 1.0 mg/kg IV TP-434.
- Trial name
- BAL (NCT01989949)
- Testing
- TP-434 (Eravacycline) reconstituted and administered via an IV infusion
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tetraphase Pharmaceuticals, Inc
Solar Lentigo, Senile Lentigo
Performance and Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in th Treatment of Brown Spots (Solar and Senile Lentigines, Post-Inflammatory Hyperpigmentation) on the Face and Hands of Asian Ethnicity Skins
CS5_4 study aim to evaluate the performance and the tolerance of 3 prototypes of cyto-selective cryotherapy treatments applied on the brown spots on the face and hands of asian ethnicity skins (chinese).
- Trial name
- NCT05886010
- Testing
- prototypes 1 everyday, prototypes 1 every week, prototypes 1 every two weeks
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Cryonove Pharma
Rheumatoid Arthritis, Ankylosing Spondylitis
99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)
This was a monocentric, open label, Phase I-IIa study. Eligible patients who signed the ICF received two single intravenous (IV) bolus of the imaging agent 99mTc-rhAnnexin V-128.
- Trial name
- NCT02328027
- Testing
- 99mTc-rhAnnexin V-128
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- Advanced Accelerator Applications
Herpes Simplex, HIV Infections
An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies
To evaluate the safety and efficacy of intermittent intravenous (IV) foscarnet in the treatment of acyclovir-resistant herpes simplex virus (HSV) infections in AIDS patients and other immunocompromised patients.
- Trial name
- NCT00002021
- Testing
- Foscarnet sodium
- Where
- 2 sites in United States
- Sponsor
- Astra USA
ER+, HER2- Advanced Breast Cancer, Metastatic Breast Cancer
Study of TFX06 in Women With Advanced Breast Cancer.
A Phase 1/2 Dose Escalation and Expansion Study of TFX06 tablet Alone in Women with ER Positive, HER2 Negative Advanced Breast Cancer
- Trial name
- NCT05927779
- Testing
- TFX06 tablet
- Where
- 2 sites in China
- Volunteers
- 74 people
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Atopic Dermatitis, Eczema, Atopic
Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream for Very Dry, Irritated to Atopic Sensitive Skin.
Multicentric, double blind, randomized, comparative study with two parallel group: study group vs placebo group. 5 visits: inclusion visit [day (D) 0] and 4 follow-up visits (D30, D60, D90, and D120).
- Trial name
- NCT05575882
- Testing
- Skin hydration, Barrier function measurement, Potential of hydrogen measurement (pH)
- Where
- 3 sites in Argentina, India and 1 more
- Volunteers
- 100 people
- Sponsor
- NAOS Argentina S.A.
Acne Vulgaris
Efficacy and Tolerance of a Derivative of Salicylic Acid and 5% Benzoyl Peroxide in Facial Acne Vulgaris
Acne vulgaris is a frequent inflammatory skin condition involving the pilosebaceous unit and affecting more than 80% of teenagers.
- Trial name
- NCT00624676
- Testing
- Lipo Hydroxy Acid, 5% benzoyl peroxide gel
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Cosmetique Active International
Solar Lentigo, Senile Lentigo
Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots.
CS5_3 aims to evaluate the tolerance and to adjust the mode of administration of 4 different conditions of cryotherapy treatments applied on the brown spots of the face and hands with 3 prototypes.
- Conditions
- Solar Lentigo, Senile Lentigo, Post-inflammatory Hyperpigmentation
- Trial name
- NCT05625815
- Testing
- Prototypes (816-v1 001) to (816-v1 050), Prototype (816-v1 051) to (816-v1 100), Prototypes (816-v1 101) to (816-v1 150)
- Where
- South Africa
- Volunteers
- 32 people
- Sponsor
- Cryonove Pharma
Solid Tumors, Multiple Myeloma
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene…
- Conditions
- Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors
- Trial name
- NCT02110563
- Testing
- DCR-MYC
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Rheumatoid Arthritis
A Trial With Humanized TNFα Monoclonal Antibody Injection by Single Dose and Dose Escalation in Healthy Subjects
This study is a randomized, double-blind and placebo-controlled trial with healthy subjects. There are 6 Groups as follows: 5mg, 15mg, 30mg, 50mg, 75mg, 100mg, and each group includes12 people.
- Trial name
- NCT02460393
- Testing
- Humanized TNFα monoclonal antibody
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Psoriasis
A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)
This study will evaluate the efficacy, tolerability, and effect on the quality of life of infliximab in adults with moderate-to-severe psoriasis who are resistant to etanercept after 12 weeks of treatment or have failed 24 weeks…
- Trial name
- TANGO (NCT00686595)
- Testing
- Infliximab
- Volunteers
- 48 people
- Sponsor
- Merck Sharp & Dohme LLC